KRRO - Korro Bio Inc Options
This article provides a detailed financial overview of Korro Bio Inc (KRRO), including its last close price, market capitalization, income, sales, and various financial ratios. It also lists key performance metrics like insider ownership, institutional ownership, profitability, and stock performance over different periods. The data covers a comprehensive range of financial health indicators and market activity for the biotechnology company.
Korro Bio, Inc.(NasdaqCM: KRRO) added to Russell 2500 Growth Benchmark
Korro Bio, Inc. (NasdaqCM: KRRO) has been added to the Russell 2500 Growth Benchmark index. The company specializes in developing genetic medicines based on RNA editing, focusing on diseases like Alpha-1 Antitrypsin Deficiency. Recent news for Korro Bio includes additions to several Russell indices and analyst reports with "Buy" ratings and price targets.
Korro Bio, Inc.(NasdaqCM: KRRO) added to Russell Microcap Growth Benchmark Index
Korro Bio, Inc. (NasdaqCM: KRRO) has been included in the Russell Microcap Growth Benchmark Index. This announcement highlights the company's growing presence in the financial markets. The biopharmaceutical company focuses on developing genetic medicines based on RNA editing for various diseases.
Korro Bio, Inc.(NasdaqCM: KRRO) added to Russell 3000E Growth Benchmark
Korro Bio, Inc. (NasdaqCM: KRRO), a clinical-stage biopharmaceutical company focused on RNA editing for genetic medicines, has been added to the Russell 3000E Growth Benchmark. The company's lead development candidate, KRRO-110, aims to treat Alpha-1 Antitrypsin Deficiency (AATD). Recent news includes an insider share sale and the selection of Krro-111 for AATD treatment, alongside several analyst upgrades.
Korro Bio, Inc. (KRRO) soars 17.6%: Is further upside left in the stock?
Korro Bio, Inc. (KRRO) experienced a significant 17.6% surge, outperforming the S&P 500, which saw a modest gain of 0.4%. This strong performance raises the question of whether the stock has further potential for growth. Investors will be observing upcoming earnings data and analyst revisions to determine the future trajectory of KRRO.
Korro Bio, Inc. Actuals & Estimates (NASDAQ:KRRO)
This article provides an overview of Korro Bio, Inc. (NASDAQ: KRRO) stock performance, analyst estimates, and financial data. It covers current stock price, historical highs and lows, market capitalization, upcoming earnings dates, and past financial results like revenue and net income.
KRRO Forecast — Price Target — Prediction for 2027
This article provides a forecast for Korro Bio, Inc. (KRRO) stock, including analyst price targets, past performance, and key financial data. According to analysts, KRRO has a max estimate of $30.00 and a min estimate of $8.00. The company's current stock price is $12.17, and it is expected to release its next earnings report on August 18, 2026.
Atlas Venture sells KRRO common stock in late May–June 2026 (KRRO)
Atlas Venture entities recently filed Rule 144 notices detailing proposed and executed sales of Korro Bio, Inc. (KRRO) common stock in May and June 2026. The filings show multiple transactions, including significant sales on June 22 and June 23, 2026, by Atlas Venture Fund XI, L.P. and Atlas Venture Opportunity Fund II, L.P. These sales include 101,579 shares for over $1.4 million on June 23, 2026, by Atlas Venture Fund XI, L.P., and reference an earlier private placement by Korro Bio in April 2024.
Atlas Venture (KRRO) sells 101,579 shares on 06/23/2026, multiple Form 144 entries
Korro Bio, Inc. (KRRO) reported multiple sales of its common stock by affiliated holders, Atlas Venture Fund XI, L.P. and Atlas Venture Opportunity Fund II, L.P., through Form 144 filings. The largest listed sale was for 101,579 shares on June 23, 2026, totaling $1,447,785.17. Other dispositions occurred between May 28, 2026, and June 23, 2026, with details on share counts and gross proceeds provided.
Form 4 Korro Bio Inc For: 24 June By Investing.com
This article from Investing.com is a regulatory filing update for Korro Bio Inc. It specifically mentions a "Form 4" filing dated June 24 and attributes the information to Reuters. The article itself is very brief, serving primarily as a notification about this financial document.
Korro Bio Insider Sold Shares Worth $2,458,582, According to a Recent SEC Filing
An insider at Korro Bio sold shares valued at $2,458,582, as disclosed in a recent SEC filing. The company is a clinical-stage biopharmaceutical firm focused on developing genetic medicines based on RNA editing for both rare and common diseases. Korro Bio's stock performance and analyst ratings are also mentioned, with several firms upgrading their outlook on the company recently.
Korro Bio director Jean Francois Formela sells $2.45m in shares
Korro Bio director Jean Francois Formela sold approximately $2.46 million in company shares across three trading days in late June 2026, executed under a Rule 10b5-1 trading plan. The sales occurred as the stock traded between $13.95 and $14.98, with the current price reflecting a strong 64% return over the past six months despite volatility. This insider sale comes amidst other company news, including the addition of KRRO-111 to its pipeline and varied analyst ratings.
Korro Bio (KRRO) director-affiliated Atlas funds sell 171K shares under 10b5-1 plan
Funds affiliated with Korro Bio director Jean Francois Formela, specifically Atlas Venture entities, sold a total of 171,405 shares of Korro Bio common stock through eight open-market transactions. These sales, executed under a pre-arranged Rule 10b5-1 trading plan adopted on April 8, 2026, occurred at prices ranging from $13.95 to $15.10 per share. Despite these sales, the Atlas funds retain substantial indirect holdings in Korro Bio, indicating the transactions are likely for portfolio management rather than a complete exit.
Form 4 Korro Bio Inc For: 24 June By Investing.com
This article from Investing.com reports on a Form 4 filing for Korro Bio Inc, specifically dated June 24. A Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a material change in the holdings of company insiders. The publication primarily serves as an announcement of this filing, without providing further details on the content of the Form 4 itself.
Form 144 Korro Bio For: 23 June By Investing.com
This article from Investing.com announces the filing of Form 144 for Korro Bio on June 23. It provides limited textual content but is surrounded by extensive financial market data, including various indices, commodity prices, and stock performances. The core message is a direct report of the Form 144 filing for Korro Bio.
Atlas Venture sells KRRO (KRRO) stock — 2,441 and 419 shares reported
Atlas Venture has filed a Form 144, indicating proposed sales of Korro Bio, Inc. (KRRO) common stock. Atlas Venture Fund XI intends to sell 2,441 shares for $34,051.95, and Atlas Venture Opportunity Fund II plans to sell 419 shares for $5,845.05, with both sales dated May 28, 2026. This filing is a routine disclosure by institutional holders and does not signify immediate proceeds for Korro Bio, Inc.
Form 144 Korro Bio For: 22 June By Investing.com
This article announces the filing of Form 144 for Korro Bio on June 22nd, as reported by Investing.com. It is a brief, technical notification, typical of financial news outlets reporting on regulatory filings. The article also includes stock market data and other news headlines.
Korro Bio, Inc. (KRRO) Soars 17.6%: Is Further Upside Left in the Stock?
Korro Bio, Inc. (KRRO) shares surged 17.6% on strong volume, likely due to investor optimism regarding its RNA-editing platform and pipeline advancements, including lead candidate KRRO-121 for hyperammonemia and KRRO-111 for Alpha-1 Antitrypsin Deficiency. Despite the stock's recent gain, analysts forecast a quarterly loss and a negative trend in earnings estimate revisions. The stock currently holds a Zacks Rank #3 (Hold).
Korro Bio, Inc. (KRRO) Soars 17.6%: Is Further Upside Left in the Stock?
Korro Bio, Inc. (KRRO) saw its shares jump 17.6% to $12.99, driven by investor optimism surrounding its RNA-editing platform and pipeline advancements, including lead candidate KRRO-121 for hyperammonemia and KRRO-111 for Alpha-1 Antitrypsin Deficiency. Despite this recent surge, the consensus EPS estimate for the upcoming quarter has been revised slightly lower, and the stock currently holds a Zacks Rank #3 (Hold). Investors are advised to monitor the stock closely for continued strength, keeping in mind the potential impact of earnings estimate revisions on near-term price movements.
Korro Bio Inc (KRRO) Technical Analysis: Support, Resistance, Indicators & Moving Averages
Korro Bio Inc (KRRO) currently holds a price momentum score of 6.96, placing it 183rd in the Biotechnology & Medical Research industry. The stock is trading between resistance at $14.69 and support at $10.58, indicating potential for range-bound swing trading. Technical indicators show a mix of buy and sell signals, with moving averages predominantly suggesting a "Buy" signal.
Korro Bio COO Chappell sells $34,309 in company stock By Investing.com
Todd Chappell, COO of Korro Bio, sold 3,168 shares of company stock for $34,309 on June 16, 2026, to cover tax withholding obligations from an RSU vesting. This sale follows strong stock performance and leaves Mr. Chappell with 16,964 direct shares. The company has also announced pipeline updates, including a new treatment candidate for AATD, leading to analyst upgrades and revised price targets.
Korro Bio Inc (KRRO) Valuation: PE, PB & Fair Value Analysis
Korro Bio Inc (KRRO) currently has a valuation score of 6.86, placing it among the lower ranks in the Biotechnology & Medical Research industry. The company's P/E ratio stands at -1.11, indicating a significant deviation from both its recent high and low P/E figures. Key valuation metrics such as P/B, P/S, and P/CF have not yet been disclosed by the company.
Korro Bio Inc (KRRO) Institutional Confidence
Korro Bio Inc (KRRO) has an institutional shareholding score of 7.00, placing it 81st out of 389 in the Biotechnology & Medical Research industry. Institutional shareholding stands at 86.30%, a 26.47% decrease quarter-over-quarter. Steven Cohen is the largest institutional shareholder, holding 1.92% of outstanding shares.
Korro Bio COO Chappell sells $34,309 in company stock
Korro Bio, Inc.'s COO, Todd Chappell, sold 3,168 shares totaling $34,309 on June 16, 2026, to cover tax withholding obligations from restricted stock unit vesting. Following the sale, Chappell directly holds 16,964 shares. The company has recently garnered attention for pipeline updates, including KRRO-111 for AATD, leading to a stock upgrade by Jones Trading.
Korro Bio COO Chappell sells $34,309 in company stock By Investing.com
Korro Bio's COO, Todd Chappell, sold 3,168 shares of company stock for $34,309 to cover tax obligations from a restricted stock unit vesting. Following the sale, Chappell directly holds 16,964 shares. The company has also announced pipeline updates, including a new treatment candidate for AATD, leading to an upgraded stock rating from Jones Trading.
Korro Bio (KRRO) SVP Dolan sells 3,383 shares to cover RSU taxes
Korro Bio's Senior Vice President of Finance, Oliver Dolan, sold 3,383 shares of common stock at a weighted-average price of $10.83 per share on June 16, 2026. This mandatory sale was conducted solely to cover tax withholding obligations associated with the vesting and settlement of restricted stock units (RSUs). Following the transaction, Dolan retains 18,099 shares, including 10,741 shares from an RSU grant set to vest on December 15, 2026, contingent on his continuous service.
[144] Korro Bio, Inc. SEC Filing
This document is a Form 144 SEC filing by Korro Bio, Inc. (KRRO) detailing a proposed sale of securities. The filing indicates a neutral impact and sentiment, outlining the filer and issuer information, the securities to be sold (3,418 shares of Common stock with an aggregate market value of $37017.28), and the acquisition details through restricted stock vesting. This is a standard notification prior to a sale of restricted stock by an insider or affiliate.
Korro Bio Inc (KRRO) Financial Health: Profitability & Balance Sheet Analysis
Korro Bio Inc (KRRO) currently holds a weak financial score of 5.59, ranking 345 out of 388 in the Biotechnology & Medical Research industry, indicating low operating efficiency. The company reported a 100.00% year-over-year decrease in its latest quarterly revenue and a 16.09% decrease in net profit. Key financial metrics for Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns have not yet been disclosed by the company.
Korro Bio Inc (KRRO) Dividends & Stock Splits: Historical Payouts and Event Timeline
Korro Bio Inc (KRRO) has not distributed any dividends over the past five years. However, the company experienced multiple stock splits in November 2023, all listed as a 50→1 merger type. The stock is currently trading at 11.050 USD, up 3.66%.
Korro Bio Inc (KRRO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey provides a revenue breakdown for Korro Bio Inc (KRRO), detailing its business segments and regional revenue contributions. However, it notes that relevant data for FY2025 and FY2024 have not yet been disclosed by the company, and only shows a United States revenue figure of $6.39M with 0.00% proportion from unspecified data. The article primarily highlights the lack of disclosed detailed financial information.
Korro Bio Inc (KRRO) Earnings Forecast: Future EPS & Revenue Growth Estimates
Korro Bio Inc (KRRO) has an earnings forecast score of 8.00, placing it 163rd in its industry. Analysts expect a target price of $9.50, with a high of $147.00 and a low of $7.00, and a "Buy" trend based on 10 analysts. The company's expected revenue for the next quarter is $214.29K, and its EPS for the next quarter is projected at $-1.27.
Korro Bio: RNA Editor Plots Way Back After AATD Study Fail - I'm Holding (NASDAQ:KRRO)
Korro Bio faces significant uncertainty after its lead RNA editing candidate, KRRO-110, failed in AATD, leading to a pipeline restructuring. The company is now focusing on KRRO-121 for hyperammonemia and a next-generation AATD candidate, KRRO-111, both of which show preclinical promise but lack clinical validation. While Korro Bio has sufficient cash to fund operations into the second half of 2028, future late-stage trials will necessitate additional capital, making the stock a high-risk, high-reward proposition until clinical data emerges.
Director at Korro Bio (NASDAQ: KRRO) awarded stock options for 14,677 shares
Korro Bio director Jean Francois Formela received a stock option grant for 14,677 shares of common stock as equity compensation. The options have an exercise price of $10.59 per share, expire on June 9, 2036, and vest in full on the earlier of one year from the grant date or the next annual meeting of stockholders, provided he continues his service. This transaction is a compensation award and not an open-market purchase.
Korro Bio (NASDAQ: KRRO) director receives 14,677 stock options grant
Korro Bio director Timothy R. Pearson was granted 14,677 stock options for Common Stock at an exercise price of $10.59 per share, with an expiration date of June 9, 2036. These options will vest in full on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders, provided he continues his service as a non-employee director. This transaction is a compensation-related grant, not a market purchase or sale, and after this grant, Pearson directly holds 14,677 stock options.
Korro Bio (KRRO) director receives 14,677 stock options at $10.59 strike
Korro Bio, Inc. Director Rachel Meyers was granted 14,677 stock options to purchase common stock at an exercise price of $10.59 per share. These options are part of her compensation and will vest in full on the earlier of one year from the grant date or the company's next annual meeting, provided she continues her service. The options are set to expire on June 9, 2036.
Korro Bio (KRRO) director Nessan Bermingham receives 14,677 stock options at $10.59
Korro Bio, Inc. Director Nessan Bermingham was granted 14,677 stock options with an exercise price of $10.59 per share, expiring on June 9, 2036. The options vest fully on the earlier of one year from the grant date or the next annual stockholders' meeting, conditional on his continued service as a non-employee director. This information was reported in a Form 4 SEC filing.
Korro Bio Stockholders Approve Directors, Pay and Auditor
Korro Bio (KRRO) stockholders approved the election of Nessan Bermingham and Rachel Meyers as Class I directors for three-year terms at their annual meeting on June 10, 2026. Shareholders also approved executive compensation on an advisory basis and ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. Despite "Spark" AI Analyst's neutral outlook due to weak financial performance, recent corporate events like an $85 million PIPE and pipeline advancements are seen as constructive.
What makes Korro Bio, Inc. (KRRO) a new buy stock
The provided content is extremely limited, containing only "MSN". As such, it is impossible to determine what makes Korro Bio, Inc. (KRRO) a new buy stock, as there is no substantive information present. The article is incomplete.
One Korro Bio Insider Raised Stake By 19% In Previous Year
One insider at Korro Bio, Mohamad Makhzoumi, purchased US$2.3 million worth of shares in the last year, demonstrating optimism for the stock. While there was also significant insider selling by the CEO recently, the overall trend over the past year shows net insider buying. Despite this, insiders only own 4.5% of the company, and the article notes some caution, recommending further investigation into potential risks before investing.
Korro Bio CEO Ram Aiyar sells $196,672 in company stock
Korro Bio CEO Ram Aiyar sold 15,152 shares of company stock worth $196,672 to cover tax obligations from a performance stock unit vesting. Following the sale, he directly holds 74,848 shares. This comes amid significant clinical advancements for Korro Bio, including new pipeline additions and upgrades from multiple analysts, although one analyst adjusted its price target downwards.
Korro Bio CEO Ram Aiyar sells $196,672 in company stock
Korro Bio CEO Ram Aiyar sold 15,152 shares of company stock worth $196,672 to cover tax obligations from a performance stock unit vesting. Despite this sale, Aiyar still directly holds 74,848 shares. The company has seen significant developments, including the addition of KRRO-111 to its pipeline for AATD and several analyst upgrades and price target adjustments.
Korro Bio director sells $39,897 in common stock
Korro Bio director Jean Francois Formela sold 2,860 shares of common stock worth $39,897 on May 28, 2026, as part of a Rule 10b5-1 trading plan. The shares were held indirectly through investment funds, Atlas Venture Fund XI, L.P., and Atlas Venture Opportunity Fund II, L.P. Following the sale, Mr. Formela maintains significant indirect holdings in Korro Bio.
Press Release: Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors
Korro Bio has expanded its Board of Directors with the appointment of Dr. Katharine Knobil, a seasoned pharmaceutical executive with extensive experience in drug development and medical affairs. Dr. Knobil's addition is expected to provide valuable expertise as Korro advances its RNA editing platform. Concurrently, David Lucchino has resigned from the board.
Piper Sandler Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $30
Piper Sandler has reiterated its Buy rating for Korro Bio (KRRO.US) and maintained its price target at $30. This indicates continued analyst confidence in the company's prospects.
Korro Bio (Nasdaq:KRRO) - Stock Analysis
This extensive analysis of Korro Bio (Nasdaq: KRRO) provides a detailed overview of its valuation, future growth prospects, past performance, financial health, and recent news. The company, which specializes in RNA-editing genetic medicines, is currently unprofitable but forecasts significant revenue growth, alongside risks such as shareholder dilution and declining earnings.
Korro Bio (KRRO) Receives a Buy from H.C. Wainwright
H.C. Wainwright analyst Mitchell Kapoor has maintained a Buy rating on Korro Bio (KRRO) with a price target of $15.00. The company reported a GAAP net loss of $19.63 million in its latest quarter, and corporate insider sentiment for the stock is positive, with an increase in insider buying. Korro Bio holds a Strong Buy consensus among analysts, with an average price target of $19.70.
Korro to Present at the 2026 Jefferies Global Healthcare Conference
Korro Bio, Inc. (Nasdaq: KRRO) announced that its CEO and President, Ram Aiyar, Ph.D., will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026, at 4:20 pm ET. Korro is a biopharmaceutical company utilizing its novel Oligonucleotide Promoted Editing of RNA (OPERA®) platform to develop genetic medicines for various diseases. The company aims to harness the body's natural RNA editing process for precise, transient single-base edits, expanding the scope of genetic medicines.
H.C. Wainwright Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $15
H.C. Wainwright has reiterated its Buy rating for Korro Bio (KRRO.US), maintaining a target price of $15 per share. This indicates the firm's continued positive outlook on the biopharmaceutical company's financial prospects and stock performance.
H.C. Wainwright Maintains Korro Bio(KRRO.US) With Buy Rating, Cuts Target Price to $15
H.C. Wainwright has reiterated its Buy rating for Korro Bio (KRRO.US) but has adjusted its price target downwards to $15. This indicates a continued positive outlook on the company's stock, despite a reduction in the expected future valuation.
Korro Bio adds AATD treatment candidate to pipeline
Korro Bio Inc. has announced the addition of KRRO-111 to its pipeline for treating alpha-1 antitrypsin deficiency (AATD), a genetic disorder. Preclinical studies have shown that KRRO-111 effectively repairs pathogenic mutations and restores functional AAT protein, reducing aggregated proteins significantly. This advancement follows recent analyst upgrades and a successful financing round, reflecting growing confidence in the company's RNA editing platform.
